Dosage Forms

With this approval, HYQVIA [Immune Globulin Infusion 10% (human) with Recombinant Human Hyaluronidase] becomes the first and only facilitated subcutaneous immunoglobulin available in Japan to treat these disorders.

The companies will use Orexo’s powder-based drug delivery technology to develop mucosal vaccines in an inhaled formulation.

This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.

Centogene NV and ROPAD consortium publish data from a landmark study identifying genetic variants that may respond to innovative cell and gene therapies.

Lilly is investing $3 billion to expand its recently acquired manufacturing facility in Wisconsin, while Amgen is investing $1 billion to expand its facility in North Carolina.

Datwyler has launched new coated plungers in its NeoFlex line that are suitable for large volume biologics.

The announcement of the pairing comes several months after Adare Pharma Solutions said it would upgrade several of its facilities, including in Milan, Italy, where the 3D printing operations will be located.

A coordinated and international response is needed to help control the latest mpox outbreak in Africa.

The ROSS FDA-3500 dual shaft mixer is equipped with independently controlled drives and is designed to efficiently produce good turnover and impart shear to a viscous batch.

The NexGen Press 45 is the latest member of GEA Pharma & Healthcare’s NexGen Press line of tablet presses.

STADA and Alvotech have launched Uzpruvo in Europe, making it the first approved biosimilar to Stelara (ustekinumab) in the European market.

Pelletization, a popular oral drug delivery method in pharmaceuticals and nutraceuticals, offers numerous benefits. This article delves into the critical parameters for formulation development and technological consideration in pelletization, elucidating its significance in advancing pharmaceutical solutions.

The companies have restructured their existing collaboration into a licensing agreement that invests in mRNA development.

Biosimilar analytical assessments focus on demonstrating biosimilarity and interchangeability with the reference biologic.

A combination of rapid sterility methods with the industry standard compendial method should ensure maximum safety.

A greater understanding of molecular and cellular biology and technological advancements are revolutionizing the field of biologics.

Technological advances are helping advance biologics development and manufacturing and reduce bottlenecks.

Advanced oral dosage forms allow for modulation of controlled- and sustained-release profiles.

Packaging and packaging line innovations are addressing the industry’s growing use of biologics.

New plans laid out by AstraZeneca will see £650 million ($828 million) be invested into the UK.

Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Given the criticality of fill/finish processes, it is clear that automation is the next technological step.

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

AstraZeneca has completed its acquisition of Icosavax, gaining the IVX-A12 vaccine candidate that targets RSV and hMPV.

GSK is expanding its respiratory biologics portfolio with its acquisition of Aiolos Bio and its novel therapy, AIO-001.

Technical, regulatory, and personnel considerations characterize pharmaceutical compounding.

Takeda has received FDA approval for HYQVIA, a subcutaneous immunoglobulin for the maintenance treatment of chronic inflammatory demyelinating polyneuropathy.

Looking at the role that RSV and pediatric medical practices play in drug shortages.

Pharmaceutical Technology Europe® spoke with Carlos Rial Calvo from FABRX, a pharmaceutical 3D printing company, at the inaugural Start-Up Market on the show floor at CPHI Barcelona 2023.